The present invention relates to methods for treating
cancer comprising utilizing a combination of
signal transduction inhibitors. More specifically, the present invention relates to combinations of so called
cell cycle inhibitors with mitogen stimulated
kinase signal transduction inhibitors, more specifically combinations of CDK inhibitors with mitogen stimulated
kinase signal transduction inhibitors, more preferably MEK inhibitors. Other embodiments of the invention relate to additional combinations of the aforesaid combinations with standard anti-
cancer agents such as cytotoxic agents, palliatives and antiangiogenics. Most specifically this invention relates to combinations of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one including salt forms, which is a selective
cyclin-dependent
kinase 4 (CDK4) inhibitor, in combination with one or more MEK inhibitors, most preferably N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-
benzamide. The aforementioned combinations are useful for treating
inflammation and
cell proliferative diseases such as
cancer and
restenosis.